5-Azacytidine Bulk Price and Supply Chain Analysis for 2026

• Market Outlook: Demand for epigenetic modifiers is driving stable bulk price trends into 2026.
• Technical Specs: CAS 320-67-2 requires strict -20°C storage and high industrial purity standards.
• Procurement: Verified suppliers provide comprehensive COA documentation and scalable manufacturing process capabilities.

The pharmaceutical landscape for nucleoside analogs continues to evolve, with 5-Azacytidine remaining a cornerstone compound for epigenetic research and oncology treatments. As a pyrimidine nucleoside analog of cytidine, this active pharmaceutical ingredient (API) functions primarily as a DNA methylation inhibitor. For procurement managers and synthetic chemists planning for the 2026 fiscal year, understanding the interplay between bulk price volatility, regulatory compliance, and synthesis scalability is critical. NINGBO INNO PHARMCHEM CO.,LTD. stands at the forefront of this supply chain, offering technical advantages that ensure consistency in large-scale production environments.

The chemical identity of this compound is precise, often referenced by its systematic name, 4-Amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one. With a molecular weight of 244.20 g/mol and a molecular formula of C8H12N4O5, the material demands rigorous handling protocols. Market data indicates that while small-scale research quantities remain accessible, the industrial sector is shifting towards validated bulk procurement strategies to mitigate supply chain disruptions. This analysis details the technical and commercial factors influencing the availability and cost of this essential intermediate.

Market Forecast for Bulk Procurement in 2026

Projecting the market trajectory for hypomethylating agents requires an assessment of global therapeutic demand. The primary application of this compound lies in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). As clinical protocols expand, the requirement for pharmaceutical-grade intermediates increases proportionally. Pricing models for 2026 are expected to stabilize, provided that raw material sourcing for the ribose and triazine components remains consistent.

However, external factors such as regulatory modifications and logistics costs can influence the final bulk price. Buyers should anticipate that premiums may apply for batches accompanied by full regulatory documentation, such as Drug Master Files (DMF) or Certificates of Analysis (COA) that meet USP or EP standards. The cost per kilogram typically decreases significantly with volume, but only when sourced from facilities capable of maintaining industrial purity levels above 98%. Suppliers who invest in robust quality control systems can offer more competitive long-term contracts, shielding buyers from spot-market fluctuations.

Technical Specifications and Synthesis Route

From a process chemistry perspective, the value of this API is defined by its impurity profile and stereochemistry. The synthesis route for 5-Azacytidine involves the coupling of a protected ribose derivative with a triazine base, followed by deprotection and purification. Maintaining the correct stereochemistry at the four defined atom stereocenters is vital for biological activity. Any deviation in the manufacturing process can lead to diastereomeric impurities that complicate downstream formulation.

Quality assurance is paramount. A comprehensive COA should detail parameters such as loss on drying, residual solvents, and heavy metals. Given the compound's sensitivity, storage temperature is a critical specification, typically requiring -20°C to prevent degradation. The topological polar surface area of 141 Ų influences its solubility and permeability, which must be accounted for during formulation development. Below is a summary of key physical and chemical properties required for vendor qualification.

Property	Specification
CAS Registry Number	320-67-2
Molecular Formula	C8H12N4O5
Molecular Weight	244.20 g/mol
Storage Temperature	-20°C
Appearance	White to Off-White Solid
Purity Standard	>98% (HPLC)

Cost Drivers for Pharmaceutical Grade Intermediates

The total cost of ownership for this intermediate extends beyond the invoice price. Logistics play a significant role, as the material often requires shipping on wet ice or under controlled frozen conditions to maintain stability during transit. Harmonized Tariff Codes, such as 29349990, must be accurately declared to prevent customs delays. Furthermore, the capability of the supplier to scale production without compromising quality is a major cost driver. Facilities that utilize advanced crystallization techniques can achieve higher yields and lower waste, passing savings onto the buyer.

When evaluating supply chain resilience, partnering with a verified global manufacturer ensures consistent batch quality and regulatory alignment. NINGBO INNO PHARMCHEM CO.,LTD. emphasizes transparency in their production capabilities, allowing clients to audit the manufacturing process remotely or on-site. This level of oversight reduces the risk of batch failure during clinical trials or commercial production. Additionally, suppliers who maintain safety stock can offer shorter lead times, which is crucial for just-in-time manufacturing schedules.

Regulatory Compliance and Documentation

Procurement teams must verify that the supplier adheres to Good Manufacturing Practices (GMP). Documentation should include evidence of conformity, stability data, and method validation reports. For markets requiring specific regional filings, such as USDMF or JDMF, the supplier must have these files active and accessible. The absence of proper documentation can lead to significant regulatory hurdles, delaying product launches. Therefore, the initial vendor qualification process should prioritize suppliers with a proven track record of successful regulatory inspections.

In conclusion, the 2026 outlook for 5-Azacytidine suggests a stable market for qualified buyers who prioritize technical excellence over lowest-cost sourcing. By focusing on industrial purity, robust synthesis route validation, and reliable logistics, pharmaceutical companies can secure their supply chains against future disruptions. Strategic partnerships with established chemical manufacturers remain the most effective method for ensuring long-term availability and cost efficiency.